神經退行性疾□□病市場：按適應症類型、藥物類型、地區劃分——規模、份額、展望、機會分析，2023-2030 年

神經退行性疾□□病是一種中樞神經系統細胞停止工作或死亡的疾病。 神經退行性疾□□病是由神經細胞結構或功能在稱為神經變性的過程中逐漸喪失引起的。 阿爾茨海默病和帕金森病是最常見的神經退行性疾□□病。 神經退行性疾□□病通常會隨著時間的推移而惡化，並且無法治愈。

市場動態：

神經退行性疾□□病患病率上升，人口老齡化加劇，對安全有效療法的需求不斷增長，公眾對神經退行性疾□□病和可用療法的認識不斷提高，強大的產品管線是預計將推動全球神經退行性疾□□病市場增長的主要因素在預測期間。

例如，2022 年 10 月，Cyclo Therapeutics 將開始一項名為 Trappsol Cyclo 的研究藥物的 2b 期試驗，該藥物用於治療早期阿爾茨海默病，目標是減少澱粉樣蛋白和 tau 蛋白。

此外，2022 年 8 月，Amneal Pharmaceuticals 向美國食品藥品監督管理局 (FDA) 提交了 IPX203 的新藥申請，IPX203 是一種用於治療帕金森病的卡比多巴/左旋多巴緩釋膠囊的新型口服製劑。

這項研究的主要特點

• 本報告對全球神經退行性疾□□病市場進行了深入分析，提供了以 2022 年為基準年的預測期（2023-2030 年）的市場規模和復合年增長率 (CAGR%) 增長情況。
• 它還闡明了各個細分市場的潛在創收機會，並描述了該市場具有吸引力的投資建議矩陣。
• 它還提供有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
• 它根據以下參數介紹了全球神經退行性疾□□病市場的主要參與者，包括公司亮點、產品組合、主要亮點、財務業績和戰略。
• 參與這項研究的主要公司包括 Amneal Pharmaceuticals Inc.、Boehringer Ingelheim International Gmbh、F. Hoffmann-La Roche、Abbvie Inc.、Merck & Co. Inc.。
• 這份報告中的見解可以讓營銷人員和企業高管就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。獎。
• 《全球神經退行性疾□□病市場》報告面向行業內的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以通過用於分析全球神經退行性疾□□病市場的各種戰略矩陣來促進決策制定。

內容

第一章調查的目的和前提

• 調查目的
• 先決條件
• 縮寫說明

第二章市場範圍

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 市場概況：按適應症類型分類
  • 按藥物類型劃分的市場概況
  • 市場概況：按地區
• 連貫機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

• 市場動態
  • 神經退行性疾□□病患病率上升
  • 嚴格的監管準則
  • 擴大對新藥的需求
• 影響分析
• 主要亮點
• 監管場景
• 產品發布/批准
• 害蟲分析
• 對 PORTER 的分析
• 合併/收購場景

第 4 章全球神經退行性疾□□病市場 - 冠狀病毒 (COVID-19) 大流行的影響

• COVID-19 流行病學
• 供應方和需求方分析
• 經濟影響

第 5 章全球神經退行性疾□□病市場：按適應症類型，2017-2030

• 帕金森病
• 阿爾茨海默氏癡呆症
• 多發性硬化症
• 亨廷頓舞蹈症
• 其他顯示類型

第 6 章全球神經退行性疾□□病市場，按藥物類型，2017-2030

• N-甲基-D-天冬氨酸受體拮抗劑
• 膽鹼酯□抑製劑
• 多巴胺激動劑
• 免疫調節劑
• 其他藥物類型

第 7 章：2017-2030 年按地區分列的全球神經退行性疾□□病市場

• 北美
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東和非洲
• 世界其他地區

第八章競爭格局

• Abbvie Inc.
• Amneal Pharmaceuticals Inc.
• Boehringer Ingelheim International Gmbh
• F. Hoffmann-La Roche
• Merck & Co. Inc.

第 9 章

• 調查方法
• 關於出版商

Neurodegenerative disease is a type of disease in which cells of the central nervous system stop working or die. Neurodegenerative disease is caused by the progressive loss of structure or function of neurons, in a process known as neurodegeneration. Alzheimer's disease and Parkinson's disease are the most common neurodegenerative diseases. Neurodegenerative disorders usually get worse over time and have no cure.

Market Dynamics:

Rise in prevalence of neurodegenerative diseases, growing geriatric population, rise in demand for safe and effective therapeutics, increasing public awareness about neurodegenerative disease and available therapeutics, and strong product pipeline are major factors expected to propel growth of the global neurodegenerative disease market over the forecast period.

For instance, in October 2022, Cyclo Therapeutics announced the launch of a Phase 2b study for its investigational drug, named Trappsol Cyclo, which targets the reduction of amyloid beta and tau to treat early Alzheimer's disease.

Moreover, in August 2022, Amneal Pharmaceuticals submitted a New Drug Application to the Food & Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa extended-release capsules for the treatment of Parkinson's disease.

Key Features of the Study:

• This report provides in-depth analysis of the global neurodegenerative disease market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global neurodegenerative disease market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Amneal Pharmaceuticals Inc., Boehringer Ingelheim International Gmbh, F. Hoffmann-La Roche, Abbvie Inc., and Merck & Co. Inc., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global neurodegenerative disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurodegenerative disease market.

Detailed Segmentation:

• Global Neurodegenerative Disease Market, By Indication Type:
  • Parkinson's Disease
  • Alzheimer's Disease
  • Multiple Sclerosis
  • Huntington Disease
  • Other Indication Types
• Global Neurodegenerative Disease Market, By Drug Type:
  • N-methyl-D-aspartate Receptor antagonists
  • Cholinesterase Inhibitors
  • Dopamine Agonists
  • Immunomodulatory Drugs
  • Other Drug Types
• Global Neurodegenerative Disease Market, By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
• Company Profiles:
  • Abbvie Inc.
  • Amneal Pharmaceuticals Inc.
  • Boehringer Ingelheim International Gmbh
  • Hoffmann-La Roche
  • Merck & Co. Inc.

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Indication Type
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rise in prevalence of neurodegenerative diseases
  • Stringent regulatory guidelines
  • Increase in demand for novel therapeutics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Neurodegenerative Disease Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Neurodegenerative Disease Market, By Indication Type, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Parkinson's Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Alzheimer's Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Multiple Sclerosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Huntington Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Other Indication Types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Neurodegenerative Disease Market, By Drug Type, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• N-methyl-D-aspartate Receptor Antagonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Cholinesterase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Dopamine Agonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Immunomodulatory Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Other Drug Types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

7. Global Neurodegenerative Disease Market, By Geography, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
• Rest of World
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)

8. Competitive Landscape

• Abbvie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amneal Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boehringer Ingelheim International Gmbh
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann-La Roche
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co. Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us